Monoclonal antibody treatment combo reduces hospitalization among high-risk patients with COVID-19

ROCHESTER, Minn. ― In an observational study, Mayo Clinic researchers report that the combination of casirivimab and imdevimab ― two monoclonal antibody treatments under Food and Drug Administration emergency use authorization ― keep high-risk patients out of the hospital when infected with mild to moderate CO VID-19. The findings appear in The Lancet's EClinicalMedicine. Nearly 1,400 Mayo Clinic patients were enrolled in the study ― 696 who received the drug combo between December 2020 and early…
Source: Mayo Clinic Minnesota News - Category: Hospital Management Source Type: news